John McKune - Kalvista Pharmaceuticals VP Fin
| KALV Stock | USD 10.15 0.83 8.91% |
Insider
John McKune is VP Fin of Kalvista Pharmaceuticals
| Age | 48 |
| Address | 55 Cambridge Parkway, Cambridge, MA, United States, 02142 |
| Phone | 857 999 0075 |
| Web | https://www.kalvista.com |
John McKune Latest Insider Activity
Tracking and analyzing the buying and selling activities of John McKune against Kalvista Pharmaceuticals stock is an integral part of due diligence when investing in Kalvista Pharmaceuticals. John McKune insider activity provides valuable insight into whether Kalvista Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Kalvista Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kalvista Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John McKune over three months ago Acquisition by John McKune of 7233 shares of Pulmonx Corp subject to Rule 16b-3 | ||
John McKune over six months ago Disposition of 254 shares by John McKune of PulmonxCorp at 9.06 subject to Rule 16b-3 |
Kalvista Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.16 in 2024, whereas Return On Tangible Assets are likely to drop (1.09) in 2024. At this time, Kalvista Pharmaceuticals' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1 M in 2024, whereas Other Current Assets are likely to drop slightly above 1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Keith CPA | Syndax Pharmaceuticals | 53 | |
| MS MD | Dyne Therapeutics | 57 | |
| Paul Ross | Mirum Pharmaceuticals | N/A | |
| Troy JD | Kura Oncology | 55 | |
| Susanna MBA | Dyne Therapeutics | 56 | |
| MSC MBA | Mirum Pharmaceuticals | 54 | |
| Alexander Nolte | Syndax Pharmaceuticals | 51 | |
| Oxana Beskrovnaya | Dyne Therapeutics | 63 | |
| Briggs MD | Syndax Pharmaceuticals | 64 | |
| Marc MD | Kura Oncology | 50 | |
| BCh BM | Kronos Bio | 40 | |
| Ronald Evans | Syndax Pharmaceuticals | 75 | |
| Jessica MD | Cogent Biosciences | 49 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Gene Kim | Dyne Therapeutics | 47 | |
| Eric Olson | Viridian Therapeutics | N/A | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Rob Henderson | Viridian Therapeutics | N/A | |
| Stephen MD | Kura Oncology | 52 | |
| Brian MBA | Immunocore Holdings | 57 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 |
Kalvista Pharmaceuticals Leadership Team
Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jarrod Aldom, Vice Communications | ||
| Nicole Sweeny, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Benjamin Palleiko, Chief President | ||
| Brian Piekos, Chief Officer | ||
| John McKune, VP Fin | ||
| Thomas MBA, CEO Director | ||
| Michael PharmD, Senior Development | ||
| Christopher Yea, Chief Development Officer | ||
| MD MBA, Chief Officer | ||
| Stephen Donnelly, Director Secretary | ||
| Rachel Morten, Senior QA | ||
| Edward Feener, Chief Scientific Officer | ||
| Brian JD, General Counsel |
Kalvista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 290.91 M | ||||
| Shares Outstanding | 49.22 M | ||||
| Shares Owned By Insiders | 1.34 % | ||||
| Shares Owned By Institutions | 98.80 % | ||||
| Number Of Shares Shorted | 6.87 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.66 X | ||||
| Price To Sales | 107.42 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.